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Progressive exercise compared with best practice advice, 
with or without corticosteroid injection, for the treatment 
of patients with rotator cuff disorders (GRASP): 
a multicentre, pragmatic, 2 × 2 factorial, randomised 
controlled trial
Sally Hopewell, David J Keene, Ioana R Marian, Melina Dritsaki, Peter Heine, Lucy Cureton, Susan J Dutton, Helen Dakin, Andrew Carr, 
Willie Hamilton, Zara Hansen, Anju Jaggi, Chris Littlewood, Karen L Barker, Alastair Gray, Sarah E Lamb, on behalf of the GRASP Trial Group*
Summary
Background Corticosteroid injections and physiotherapy exercise programmes are commonly used to treat rotator cuff 
disorders but the treatments’ effectiveness is uncertain. We aimed to compare the clinical effectiveness and cost-
effectiveness of a progressive exercise programme with a single session of best practice physiotherapy advice, with or 
without corticosteroid injection, in adults with a rotator cuff disorder.
Methods In this pragmatic, multicentre, superiority, randomised controlled trial (2 × 2 factorial), we recruited patients 
from 20 UK National Health Service trusts. We included patients aged 18 years or older with a rotator cuff disorder 
(new episode within the past 6 months). Patients were excluded if they had a history of significant shoulder trauma 
(eg, dislocation, fracture, or full-thickness tear requiring surgery), neurological disease affecting the shoulder, other 
shoulder conditions (eg, inflammatory arthritis, frozen shoulder, or glenohumeral joint instability), received 
corticosteroid injection or physiotherapy for shoulder pain in the past 6 months, or were being considered for surgery. 
Patients were randomly assigned (centralised computer-generated system, 1:1:1:1) to progressive exercise (≤6 sessions), 
best practice advice (one session), corticosteroid injection then progressive exercise, or corticosteroid injection then 
best practice advice. The primary outcome was the Shoulder Pain and Disability Index (SPADI) score over 12 months, 
analysed on an intention-to-treat basis (statistical significance set at 1%). The trial was registered with the International 
Standard Randomised Controlled Trial Register, ISRCTN16539266, and EuDRACT, 2016-002991-28.
Findings Between March 10, 2017, and May 2, 2019, we screened 2287 patients. 708 patients were randomly assigned 
to progressive exercise (n=174), best practice advice (n=174), corticosteroid injection then progressive exercise (n=182), 
or corticosteroid injection then best practice advice (n=178). Over 12 months, SPADI data were available for 
166 (95%) patients in the progressive exercise group, 164 (94%) in the best practice advice group, 177 (97%) in the 
corticosteroid injection then progressive exercise group, and 175 (98%) in the corticosteroid injection then best 
practice advice group. We found no evidence of a difference in SPADI score between progressive exercise and best 
practice advice when analysed over 12 months (adjusted mean difference –0·66 [99% CI –4·52 to 3·20]). We also 
found no evidence of a difference between corticosteroid injection compared with no injection when analysed over 
12 months (–1·11 [–4·47 to 2·26]). No serious adverse events were reported.
Interpretation Progressive exercise was not superior to a best practice advice session with a physiotherapist in 
improving shoulder pain and function. Subacromial corticosteroid injection provided no long-term benefit in patients 
with rotator cuff disorders.
Funding UK National Institute for Health Research Technology Assessment Programme.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Shoulder pain is common, with approximately 1% of 
adults aged 45 years and older presenting to primary care 
services with a new episode of shoulder pain each year,1 
accounting for 2·4% of all general practitioner (GP) 
consultations in the UK.2 Disorders of the rotator cuff are 
the most common cause, accounting for 70% of cases.1 
Rotator cuff disorders are often associated with substan tial 
and persistent disability and pain and approximately half 
of patients continue to have pain or functional limitations 
for up to 2 years.2 Most problems with shoulder pain are 
managed in primary care by physiotherapists and GPs. 
The aim of treatment is to improve pain and shoulder 
function. Treatment options include rest, advice, analgesia, 
non-steroidal anti-inflammatory drugs, exercise, manual 
therapy, and corticosteroid injections.3
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Evidence from small, short-term trials suggests that 
physiotherapist-prescribed exercise is promising. How-
ever, a Cochrane review highlighted the insufficient 
evidence about the treatment’s long-term clinical 
effectiveness and cost-effectiveness.4 Despite widespread 
provision, uncertainty exists about which types of exercise 
and levels of physiotherapy supervision are associated 
with the best outcomes. This evidence is limited by 
problems in study design and lack of comparator 
groups.5,6 Progres sive resistance training to improve 
muscular strength, whether supervised or home based, 
has been identified as a core component of exercise for 
patients with rotator cuff disorders.7 Subacromial 
corticosteroid injections are commonly used to reduce 
local tissue inflammation and pain. Compared with 
placebo, corticosteroid injections have short-term benefit 
in the shoulder,8 although the longer-term benefits 
and harms are not known.9 Corticosteroid injections are 
being used increasingly in clinical practice alongside 
physiotherapy for the manage ment of people with rotator 
cuff disorders;3 hence justification for investigating 
corticosteroid injection in the GRASP (Getting it Right: 
Addressing Shoulder Pain) trial alongside physiotherapist-
prescribed exercise.
The aim of the GRASP trial was to compare the clinical 
effectiveness and cost-effectiveness of two interventions 
Research in context
Evidence before this study
A Cochrane review published in 2016 highlighted insufficient 
evidence about the long-term clinical and cost-effectiveness of 
physiotherapy for the treatment of patients with rotator cuff 
disorders despite the treatment’s widespread provision. 
Evidence from several small trials with short-term follow-up 
also raised uncertainty about which types of exercise and 
delivery mechanisms were associated with best outcomes. 
We searched MEDLINE, Embase, and CINAHL to identify new 
evidence relevant to the GRASP (Getting it Right: Addressing 
Shoulder Pain) trial (date of last search June 30, 2020; 
see appendix p 20 for search terms). From an initial 
2354 records, we identified seven trials published between 
2013 and 2020, comparing the effects of supervised exercise 
versus unsupervised exercise, or no intervention, in people with 
a rotator cuff disorder (excluding those who required surgery). 
The quality of trials was variable and considerable 
heterogeneity meant we could not combine data from studies. 
All trials were small apart from two moderate sized trials. 
Only two of the seven trials reported on the effect of exercise on 
shoulder pain and function at 12 months. Most of the trials 
concluded that little or no difference existed between 
supervised and unsupervised exercise at 6 and 12 months, 
with the exception of the SUPPORT trial, which showed a 
benefit of supervised exercise compared with an exercise leaflet 
at 6 months but not at 12 months. At the time of planning the 
GRASP trial, a systematic review showed that in comparison 
with placebo, corticosteroid injection had short-term benefit 
for treating patients with tendinopathy, although uncertainty 
existed regarding the injection’s use in patients with rotator 
cuff disorders. We searched MEDLINE, Embase, Allied and 
Complementary Medicine Database, CINAHL, the Cochrane 
Central Register of Controlled Trials, ClinicalTrials.gov, and the 
WHO International Clinical Trials Registry to identify new 
evidence relevant to the GRASP trial (date of last search 
June 30, 2020; see appendix p 20 for search terms). From an 
initial 794 records, we identified one small trial (n=50) 
comparing the effects of corticosteroid injection versus no 
injection in patients with a rotator cuff tear, which found no 
difference in shoulder pain and function when analysed at 
3 months or 6 months. We identified an additional ten trials 
comparing the effects of corticosteroid injection with placebo 
injection, of which four were judged as suitable for inclusion in 
a meta-analysis. The remaining trials could not be included 
because of either incomplete or incompatible outcome data. 
In these trials, corticosteroid injection showed a benefit over 
placebo in the short term but not the medium term for 
shoulder pain and function. No trials provided outcome data 
beyond 6-month follow-up and none reported any serious 
adverse events as a result of injection.
Added value of this study
To our knowledge, the GRASP trial is the largest randomised 
controlled trial to date that has assessed the effects of exercise 
interventions, with or without the use of subacromial 
corticosteroid injection, in adults with a new episode of shoulder 
pain attributable to a rotator cuff disorder. Our findings during 
12-month follow-up showed that the progressive exercise 
intervention was not superior to a best practice advice session 
with a physiotherapist. Subacromial corticosteroid injection was 
not superior to having no injection during 12-month follow-up, 
apart from modest improvement in shoulder pain and function 
at 8 weeks; the greatest benefit being in those with worse pain 
and functional impairment. The health economic comparison 
found that best practice advice in combination with 
corticosteroid injection is expected to be the most cost-effective, 
although some uncertainty remains around this conclusion.
Implications of all the available evidence
The GRASP trial shows that a single face-to-face session with a 
physiotherapist is likely to be more cost-effective and is not 
significantly different in terms of clinical outcomes when 
compared with a comprehensive physiotherapy intervention of 
up to six face-to-face sessions. This finding is particularly 
important given the incidence of rotator cuff disorders and the 
need to develop cost-effective and pragmatic methods of 
dealing with this high volume of conditions. Subacromial 
corticosteroid injection provides a modest short-term but no 
long-term benefit, as seen in other trials, and was associated 
with participants being more likely to report doing their 
exercises as advised.
See Online for appendix
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in adults with a new episode of shoulder pain attributable 
to a rotator cuff disorder: (1) an individually tailored, 
progressive exercise programme prescribed and super-
vised by a physiotherapist versus a best practice advice 
session with a physiotherapist; and (2) subacromial 
corticosteroid injection versus no injection.
Methods
Study design and participants
We did a multicentre, pragmatic, superiority, randomised 
controlled trial using a 2 × 2 factorial design. Patients aged 
18 years or older were recruited from 20 UK National 
Health Service (NHS) trusts. Patients were eligible if 
they had a diagnosis of shoulder pain attributable to a 
rotator cuff disorder (eg, cuff tendonitis, impingement 
syndrome, tendinopathy, or rotator cuff tear) that had 
started within the past 6 months. We used the diagnostic 
criteria set out in the British Elbow and Shoulder Society 
(BESS) guidelines.3 Patients were excluded if they had a 
history of significant shoulder trauma (eg, dislocation, 
fracture, or full-thickness tear requiring surgery), neu-
rological disease affecting the shoulder, other shoulder 
conditions (eg, inflammatory arthritis, frozen shoulder, 
or glenohumeral joint instability), received corticosteroid 
injection or physiotherapy for shoulder pain in the past 
6 months, or were being considered for surgery. Detailed 
criteria are in the protocol.10 After patients were assessed 
for eligibility, informed written consent was obtained 
from all trial participants by a research facilitator trained 
in Good Clinical Practice at each participating site. Ethics 
approval was obtained from the National Research 
Ethics Service (NRES Berkshire B Research Ethics 
Committee: 16/SC/0508). The trial protocol,10 statistical 
analysis plan (SAP),11 and health economics analysis plan 
have been published previously.12
Randomisation and masking
Consented participants were randomly assigned to 
one of four groups: (1) progressive exercise programme 
(a progressive home exercise programme that was 
individually tailored and prescribed and supervised by a 
physiotherapist involving up to six face-to-face sessions 
over 16 weeks), (2) best practice advice (one face-to-
face session with a physiotherapist and home exercise 
programme supported by high quality self-management 
materials); (3) progressive exercise programme preceded 
by a subacromial corticosteroid injection; or (4) best 
practice advice session preceded by a subacromial 
corticosteroid injection.
Randomisation (1:1:1:1) was done by an independent 
research facilitator using the centralised computer ran-
domisation service provided by the Oxford Clinical Trials 
Research Unit once the patient was enrolled and baseline 
questionnaire completed. Randomisation was computer 
generated and stratified by site, age (18–35 years, 
>35 years) and sex, using variable block sizes. We could 
not mask physiotherapists or study participants once 
treatment allocation was revealed. When practical, team 
members were masked until after data analysis was 
complete. Trial statisticians had access to treatment 
assignment during the study for the purposes of data 
monitoring and safety. Data entry personnel entered data 
from anonymised questionnaires, which included some 
details on treatments received.
Procedures
Subacromial corticosteroid injection was delivered 
before the progressive exercise or best practice advice 
intervention and given predominately by extended-scope 
physiotherapists with an appropriate post-registration 
qualification. Appointments were coordinated so that 
participants would receive their injection within 10 days 
of randomisation. In accordance with the trial protocol, 
the corticosteroid injected was either methylpred-
nisolone acetate (≤40 mg) or triamcinolone acetonide 
(≤40 mg), as per local treatment protocols. The local 
anaesthetic was either 1·0% lidocaine (≤5 mL) or 
0·5% bupivacaine hydrochloride (≤10 mL). The 
choice and dose of corticosteroid and local anaesthetic 
(including volume), including the injection site, was 
recorded for each participant. A second injection could 
be given after 6 weeks in accordance with the trial 
protocol for patients who received good initial benefit 
from their first injection. Because of existing evidence 
of the greater effectiveness of corticosteroid injection 
compared with placebo for short-term management, we 
excluded the use of placebo injection from our protocol. 
Full details of the exercise interventions have been 
reported previously13 and here described in brief.
Participants randomly assigned to the progressive 
exercise intervention received up to six individual face-to-
face sessions with a physiotherapist over 16 weeks. These 
sessions included a behavioural component to encourage 
adherence to the exercises. We chose the number of 
sessions, spread over this time, to enable progression of 
the intensity of exercise and a sufficient time for a 
physiological response in the neuromuscular system. 
Appointments were coordinated so that participants 
would start their first session within 14–28 days of 
randomisation. The initial session allowed up to 60 min 
for an initial examination of the shoulder and initial 
prescription of exercises. Thereafter, patients received up 
to five sessions, each 20–30 min, for the physiotherapist 
to progress or regress the exercise prescription using a 
standardised protocol.13 Exercises focused on movements 
commonly affected by a rotator cuff disorder: resisted 
external rotation, flexion, and abduction of the shoulder. 
Participants were given a folder containing an advice 
booklet, exercise action planner, diary, and instructions 
on their exercise programme set up in collaboration with 
the physiotherapist. Resistance bands were issued as 
required. Participants were asked to do their exercises 
5 days per week, with two non-consecutive recovery days. 
Physiotherapists recorded the number of treatment 
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sessions attended by each participant. The intervention 
was designed to support participants through a progres-
sive dose of exercises and to optimise adherence to the 
home exercise plan.
Participants randomly assigned to the best practice 
advice intervention received a single individual face-to-
face session with a physiotherapist, lasting up to 
60 min. As per the progressive exercise intervention, 
appoint ments were coordinated so that participants 
would attend their session within 14–28 days of 
randomisation. Participants also received the same 
initial shoulder examination and advice booklet (with 
exercise action planner, diary, and resistance band) but 
the exercise programme was different. Participants 
Figure 1: Trial profile
All participants with at least 
one follow-up timepoint SPADI 
outcome and the baseline 
variables used in the model 
were included in the primary 
outcome analysis. 
GRASP=Getting it Right: 
Addressing Shoulder Pain. 
SPADI=Shoulder Pain and 
Disability Index. *Reasons for 
not receiving best practice 
advice were participant did not 
attend session (n=5), 
withdrawal (n=4), or other 
medical condition (n=3). 
†Reasons for not receiving 
injection only were participant 
declined treatment (n=2) or 
contraindicated (n=1 taking 
anticoagulants and n=1 
previous reaction to injection). 
‡Reasons for not receiving best 
practice advice only were 
participant did not attend 
session (n=5), other medical 
condition (n=2), received 
progressive exercise in 
error (n=3). §Reasons for not 
receiving injection and best 
practice advice were participant 
did not attend session (n=1), 
participant declined 
treatment (n=2), other medical 
condition (n=2), or previous 
reaction to injection and 
received non-GRASP treatment 
(n=1). ¶Reasons for not 
receiving progressive exercise 
were participant did not attend 
session (n=3), received best 
practice advice in error (n=2), 
received injection in error 
(n=1), received non-GRASP 
treatment (n=1), or withdrawal 
(n=1). ||Reasons for not 
receiving injection only were 
participant declined treatment 
(n=5) or clinician declined 
treatment (n=3). **Reasons for 
not receiving progressive 
exercise only were received 
best practice advice in error 
(n=2), received non-GRASP 
treatment (n=3), other medical 
condition (n=1), or participant 
did not attend session (n=1). 
††Reasons for not receiving 
injection and progressive 
exercise were participant did 
not attend session (n=2) or 
other medical condition (n=1).
182 allocated to corticosteroid 
injection and progressive 
exercise
164 received allocated treatment
8 did not receive injection only||
7 did not receive progressive 
exercise only**
3 did not receive injection and 
progressive exercise††
182 completed baseline study visit 
169 completed 8-week follow-up
163 completed 6-month follow-up
161 completed 12-month follow-up 
5 withdrew from intervention
1 withdrew from intervention 
then died
 
177 included in primary outcome 
analysis
5 not included in analysis 
174 allocated to progressive exercise
programme only
166 received allocated treatment
8 did not receive allocated 
treatment¶
 
172 completed baseline study visit 
157 completed 8-week follow-up 
151 completed 6-month follow-up 
153 completed 12-month follow-up
1 completely withdrew
2 withdrew from intervention 
3 withdrew from intervention 
and follow-up 
1 died 
166 included in primary outcome 
analysis
8 not included in analysis
 
178 allocated to corticosteroid 
injection and best practice 
advice
158 received allocated treatment
4 did not receive injection only†
10 did not receive best practice 
advice only‡
6 did not receive injection and 
best practice advice§
178 completed baseline study visit 
165 completed 8-week follow-up 
158 completed 6-month follow-up
161 completed 12-month follow-up
4 withdrew from intervention 
3 withdrew from intervention 
and follow-up
175 included in primary outcome 
analysis
3 not included in analysis 
 
174 allocated to best practice advice 
only 
162 received allocated treatment
12 did not receive allocated 
treatment*
174 completed baseline study visit 
150 completed 8-week follow-up 
143 completed 6-month follow-up 
143 completed 12-month follow-up
3 withdrew from intervention 
4 withdrew from intervention 
and follow-up
164 included in primary outcome 
analysis




576 declined to participate 
 175 not interested in taking part in research
 39 did not want to be randomly assigned
 38 preference for receiving injection 
 158 preference for not receiving injection 
 6 did not want to be randomly assigned to progressive 
exercise 
 8 did not want to be randomised to best practice advice
 80 unable to attend treatment sessions
 20 preferred not to say
 52 other or no information
2287 patients screened 
1003 did not meet eligibility criteria
 94 history of significant shoulder trauma 
 23 neurological disease affecting shoulder
 434 other shoulder disorder
 167 received injection in past 6 months 
 31 contraindications to injection
 32 did not speak English
 59 unable to contact to arrange appointment
 132 symptoms >6 months
 31 other
330 participants who received no 
injection included in primary 
outcome analysis
352 participants who received 
injection included in primary 
outcome analysis
339 participants who received best 
practice advice included in 
primary outcome analysis
343 participants who received 
progressive exercise included in 
primary outcome analysis
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were given a simple set of self-guided exercises (with 
access to exercise videos) that could be progressed and 
regressed depending on their capability. The exercises 
were designed using similar concepts to the progressive 
exercise intervention, such as increased resistance and 
done five times per week, but these were a simpler 
range of exercise options that were not supervised.13
Physiotherapists delivering progressive exercise and 
best practice advice were trained separately by a GRASP 
trial research physiotherapist and had access to a 
comprehensive intervention manual. A rigorous quality 
control programme was done to ensure intervention 
fidelity.
All participants were advised they could take over-the-
counter analgesia as required, in accordance with the 
BESS guidelines.3 Participants could seek other forms of 
treatment during the follow-up period of the trial but 
were informed they should use standard routes to do so. 
Additional treatments were recorded as a treatment 
outcome.
Outcomes
The primary outcome was shoulder pain and function 
over 12 months after randomisation, measured using 
the Shoulder Pain and Disability Index (SPADI),14 a 
13-item measure of patient-reported outcomes in which 
each item is scored on a 0–10 numerical rating scale 
(10 being the worst score). Secondary outcomes were 
SPADI five-item pain subscale and SPADI eight-item 
function subscale (SPADI subscale items were summed 
and converted to a 0–100 scale, with higher values 
denoting more pain or disability); EQ-5D-5L;15 fear-
avoidance belief questionnaire (physical activity five-
item subscale);16 pain self-efficacy questionnaire (short 
form);17 insomnia severity index;18 participant global 
impression of change questionnaire;19 serious adverse 
events; return to desired activities, including work, social 
life, and sport activities; participant exercise adherence; 
health resource use; additional out-of-pocket expenses; 
and work absence. Measurements were collected at 
baseline and then by postal questionnaires at 8 weeks, 
6 months, and 12 months after randomisation. 
Telephone follow-up was used to contact those who did 
not respond or fully complete the returned questionnaire.
Statistical analysis
The target sample size was 704 participants, based on 
90% power to detect a minimally clinically important 
between-group difference of 8 points on the SPADI total 
scale,20 assuming a baseline SD of 24·3.21 This difference 
is equivalent to a standardised effect size of 0·33, 
which required a sample size of 550 participants. NCSS 
was used to calculate sample size. Allowing for a potential 
loss to follow-up at 12 months of 20% increased the 
sample size to 688 participants. We further increased 
the sample size to 704 participants to take into account the 
potential for a small clustering effect by physiotherapist 
(interclass correlation 0·001). The sample size assumed 
no interaction effect and was powered for the two main-
effect comparisons: (1) progressive exercise versus best 
practice advice to investigate the effects of progressive 
exercise and (2) subacromial corticosteroid injection 
versus no injec tion to investigate the effects of 
corticosteroid injec tion. This number of participants 
provided 80% power and 5% significance to detect an 
interaction with a stan dardised effect size of 0·35 or 
more, if an interaction effect did exist.
All analyses were on an intention-to-treat basis unless 
specified as otherwise. The presence of an interaction 
effect was assessed before testing the intervention 
effects on the primary outcome. The difference in 
SPADI between intervention groups was estimated 
over the 12-month period and at each data collection 
time point using a repeated-measures linear mixed-















Injection received ·· 168 (94%) ·· 171 (94%)
Injection not received ·· 10 (6%) ·· 11 (6%)
Did not attend ·· 1 (<1%) ·· 2 (1%)
Participant declined ·· 4 (2%) ·· 4 (2%)
Clinician declined ·· 5 (3%) ·· 5 (3%)
Received extra injection ·· 0 ·· 2 (1%)
Completed exercise treatment‡ 162 (93%) 162 (91%) 138 (79%) 139 (76%)
Partial exercise completion§ ·· ·· 29 (17%) 33 (18%)
Received no treatment 12 (7%) 16 (9%) 7 (4%) 10 (5%)
Did not attend or unable to contact 5 (3%) 6 (3%) 3 (2%) 3 (2%)
Withdrawal or declined 4 (2%) 2 (1%) 1 (<1%) 0
Other condition 3 (2%) 4 (2%) 0 2 (1%)
Received wrong trial intervention 0 3 (2%) 2 (1%) 2 (1%)
Received non-GRASP treatment 0 1 (<1%) 1 (<%) 3 (2%)
Median number of sessions (IQR) 1 (1–1) 1 (1–1) 4 (3–6) 4 (3–5)
Completed session 1 162 (93%) 162 (91%) 167 (96%) 172 (95%)
Completed session 2 ·· ·· 161 (93%) 160 (88%)
Completed session 3 ·· ·· 144 (83%) 136 (75%)
Completed session 4 ·· ·· 101 (58%) 100 (55%)
Completed session 5 ·· ·· 72 (41%) 69 (38%)
Completed session 6 ·· ·· 44 (25%) 38 (21%)
Participants who received additional 
sessions
3 (2%) 5 (3%) 3 (2%) 2 (1%)
Additional contact sessions¶ 4 6 3 5
Telephone 2 1 0 1
Face to face 2 5 3 4
Data are n, n (%), or median (IQR). GRASP=Getting it Right: Addressing Shoulder Pain. *Maximum one session of 
best practice advice. †Up to six sessions of progressive exercise. ‡For best practice advice, at least one session attended. 
For progressive exercise, six sessions attended or discharged by clinician because treatment completed (as marked on 
treatment log), discharged by clinician following patient-initiated follow-up period with no further contact, or referred 
on for further investigation or treatment. §Defined as at least one session attended. ¶Some participants received more 
than one additional contact.
Table 1: Intervention received by treatment group
For more on NCSS see 
https://www.ncss.com
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age, sex, and baseline SPADI, and random intercepts 
by centre, physiotherapist, and observations within 
participant. In the SAP,11 we clarified prespecification of 
the primary outcome measure as being over 12 months, 
not at 12 months, as described in the protocol.10 This 
prespecification of the primary outcome measure better 
reflects the planned method of analysis described in the 
protocol, which used a linear mixed longitudinal model. 
The data monitoring and ethics committee approved 
the SAP before the analysis was done and provided a 
blinded review of the sample size assumptions after 
338 participants were recruited and no changes were 
made to the final sample size. Prespecified subgroup 
analyses included age (≥65 years), sex, smoking status, 
increased baseline SPADI score (≥50), and increased 
baseline pain self-efficacy score (≥8). Secondary out-
comes were analysed using the same methods as the 
primary outcome.
A complier average causal effect (CACE) analysis was 
used to investigate the role of compliance on the 
treatment effect. Compliance with intervention was 
defined in the SAP11 for progressive exercise as 
participants having been signed off for completing 
treatment or if they received all six physiotherapy 
sessions and for the injection as receiving the injection.
Statistical significance was set at 1% and corresponding 
99% CIs for the primary outcome analyses. For all other 
outcomes, 5% and 95% CIs were reported. All statistical 
analyses were done using Stata (version 15). The trial was 
registered with the International Standard Ran domised 
Controlled Trial Register, ISRCTN16539266, and 
EuDRACT, 2016-002991-28.
Health economic analyses were done in accordance with 
the National Institute for Health and Care Excellence 
reference case.22 The analysis was done on an intention-to-
treat basis with multiple imputation for missing data. The 
base-case analysis was done from an NHS and personal 
social services (PSS) perspective and included the cost over 
12 months of delivering each intervention, physio therapist 
training, additional medication costs, visits to primary 
and secondary health-care professionals, outpatient 
appointments, and hospital stays. Costs were calculated 
using national UK unit costs expressed in British Pounds 
Sterling at 2019 prices. Quality-adjusted life-years (QALYs) 
were estimated from EQ-5D-5L data collected at baseline, 
8 weeks, 6 months, and 12 months. Mean costs and 
mean QALYs were used to derive the incremental cost-
effectiveness ratio. Net monetary benefit statistics were 
calculated as QALYs times willingness to pay threshold 
minus cost for comparisons between treatment groups. 
The base-case economic analysis was prespecified as 
regression analysis with an interaction term adjusting for 
age, sex and baseline utility. Regression analysis without 
interac tion terms alongside further scenarios was used as 
a sensitivity analysis to assess whether assuming additive 
effects changed the conclusions of the analysis.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results
Between March 10, 2017, and May 2, 2019, 2287 par ticipants 











Age, years 55·9 (13·1) 56·5 (12·4) 54·6 (13·7) 54·8 (13·2)
18–35* 11 (6%) 13 (7%) 14 (8%) 17 (9%)
≥36 163 (94%) 165 (93%) 160 (92%) 165 (91%)
Sex*
Male 87 (50%) 89 (50%) 90 (52%) 93 (51%)
Female 87 (50%) 89 (50%) 84 (48%) 89 (49%)
Ethnicity
White 160 (92%) 167 (94%) 154 (89%) 167 (92%)
Other 14 (8%) 11 (6%) 18 (10%) 15 (8%)
Missing 0 0 2 (1%) 0
Marital status
Married or civil union 118 (68%) 107 (60%) 114 (66%) 120 (66%)
Living with partner 24 (14%) 23 (13%) 22 (13%) 24 (13%)
Other 32 (18%) 48 (27%) 36 (21%) 38 (21%)
Missing 0 0 2 (1%) 0
























<18·5 3 (2%) 1 (<1%) 0 0
18·5 to <25·0 51 (29%) 51 (29%) 50 (29%) 53 (29%)
25·0 to <30·0 68 (39%) 63 (35%) 73 (42%) 70 (39%)
≥30·0 52 (30%) 61 (34%) 47 (27%) 57 (31%)
Missing 0 2 (1%) 4 (2%) 2 (1%)
Smoking status
Never smoked 85 (49%) 100 (56%) 99 (57%) 101 (56%)
Former smoker 66 (38%) 66 (37%) 61 (35%) 63 (35%)
Current smoker 23 (13%) 12 (7%) 12 (7%) 18 (10%)












Left shoulder 89 (51%) 78 (44%) 83 (48%) 82 (45%)
Right shoulder 78 (45%) 94 (53%) 84 (48%) 93 (51%)
Both shoulders 7 (4%) 6 (3%) 5 (3%) 7 (4%)
Missing 0 0 2 (1%) 0
Hand dominance
Left handed 13 (8%) 16 (9%) 21 (12%) 21 (12%)
Right handed 157 (90%) 153 (86%) 148 (85%) 158 (87%)
Both 4 (2%) 9 (5%) 3 (2%) 3 (2%)
Missing 0 0 2 (1%) 0
(Table 2 continues on next page)
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eligible. 708 (55%) agreed to participate and were randomly 
assigned to either progressive exercise (n=174 [25%]); best 
practice advice (n=174 [25%]); progressive exercise preceded 
by subacromial cortico steroid injection (n=182 [26%]); or 
best practice advice preceded by subacromial corticosteroid 
injection (n=178 [25%]; figure 1).
Most participants received treatment as allocated 
(table 1). Across intervention groups, high protocol 
adherence was achieved in terms of the delivery, type, 
and content for the injection, progressive exercise, and 
best practice advice interventions. 53 physiotherapists 
delivered corticosteroid injections to 329 (97%) partici-
pants and three doctors to ten (3%) participants. Progres-
sive exercise was delivered by 104 physiotherapists to 
339 participants and best practice advice was delivered by 
83 physiotherapists to 324 participants. Two physio-
therapists swapped groups during the trial because of 
staffing issues and delivered both interventions. We 
found no difference in attendance rates between those 
receiving progressive exercise or best practice advice 
and those who received the intervention in conjunction 
with corticosteroid injection (table 1). Participants who 
received the injection were more likely to do their 
exercises as advised (ie, 5 days per week), compared with 
those did not receive the injection (appendix p 5).
Follow-up questionnaires were obtained for 618 (87%) 
participants at 12 months, 615 (87%) at 6 months, and 
641 (91%) at 8 weeks. Overall, 26 (4%) participants withdrew 
from the trial, 15 from the intervention delivery only and 
ten from both the intervention and follow-up questionnaire 
completion (figure 1). Numbers of patient withdrawals 
were similar across intervention groups (figure 1).
Participant characteristics are shown in table 2. 
Participants had a mean age of 55·5 years (SD 13·1), 
49% were female, 51% were male, and mean symptom 
duration was 4 months (IQR 3–6; table 2). Intervention 
groups were well matched in terms of demographic data 
and clinical and generic health-related quality of life 
measures (table 2). The overall mean baseline SPADI 
score was 54·1 (SD 18·5), with higher baseline levels of 
shoulder pain compared with impairment in shoulder 
function (table 2).
Overall, we found a substantial improvement in SPADI 
score in each group over 12 months (table 3; appendix p 7). 
We found no evidence of a statistically significant 
interaction effect on the primary outcome between 
progressive exercise and injection over 12 months (interac-
tion coefficient 2·17 [95% CI –2·96 to 7·31]; p=0·41). At 
8 weeks the interaction was 3·41 (–3·24 to 10·06; p=0·31), 
at 6 months –1·88 (–9·98 to 6·22; p=0·65), and at 
12 months 2·25 (–5·76 to 10·26; p=0·58). The primary 
outcome analysis is therefore presented for the two main 
effect comparisons as prespecified in the SAP (appendix 
pp 7–8).
Over 12 months, we found no evidence of a difference 
in SPADI score between the progressive exercise 
intervention and best practice advice (adjusted mean 
difference –0·66 [99% CI –4·52 to 3·20]; figure 2). We 
found no difference between progressive exercise and 
best practice advice at 8 weeks, 6 months, or 12 months 
(–3·10 [–7·85 to 1·64]; figure 2). Compliance with 
the progressive exercise intervention did not have a 
significant effect on the primary outcome (CACE 
adjusted mean difference –0·27 [95% CI –2·69 to 2·16]; 
p=0·83; table 3). Over 12 months, we found no evidence 
of a difference in SPADI scores between patients who 
received the injection and those who did not (adjusted 
mean difference –1·11 [–4·47 to 2·26]). We also found 
no difference between injection and no injection at 
6 months and 12 months (1·93 [–2·41 to 6·27; figure 2). 
We found a small difference in SPADI score at 8 weeks 
(–5·64 [–9·93 to –1·35]), in favour of injection. Com-
pliance with injection did not have a significant effect on 
the primary outcome (CACE adjusted mean difference 
–1·50 [–3·61 to 0·61]; p=0·16; table 3).
Table 4 presents the adjusted analysis results for each 
of the secondary outcomes (unadjusted results are 
provided in the appendix [pp 9–10]). We found no 
evidence of a difference between progressive exercise 
and best practice advice for secondary outcome measures, 
other than improvements in patient-reported global 











(Continued from previous page)
Current work status
Retired 44 (25%) 50 (28%) 40 (23%) 49 (27%)
Semi-retired 13 (8%) 10 (6%) 9 (5%) 7 (4%)
Employed 84 (48%) 91 (51%) 98 (56%) 82 (45%)
Other 33 (19%) 27 (15%) 25 (14%) 43 (24%)
Missing 0 0 2 (1%) 1 (<1%)
SPADI score
























































Outcomes were collected using patient-reported questionnaires. A participant could choose not to answer a specific 
question and therefore N might be different for some outcome measures. Data are mean (SD) or n (%). SPADI=Shoulder 
Pain and Disability Index. FABQ PA=fear-avoidance beliefs questionnaire physical activity. PSEQ-2=pain self-efficacy 
questionnaire two-item short form. ISI=insomnia severity index. RDA=return to desired activities. *Stratification factor 
used in randomisation.
Table 2: Baseline characteristics
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12 months, at 6 months, and at 12 months timepoints. 
We found no evidence of a difference between 
corticosteroid injection and no injection for secondary 
outcome measures, except for at 8 weeks, when injection 
resulted in an improvement in shoulder pain, shoulder 
function, health-related quality of life, sleep disturbance, 
return to desired activities, and global impression of 
treatment (table 4).
We found no difference in prespecified subgroup 
analyses over 12 months for the primary outcome, with 
the exception of corticosteroid injection, in which the 
effect was stronger at 8 weeks in participants with a 
higher baseline SPADI score (adjusted MD –9·67 
[99% CI –15·37 to –3·97]), compared with those who 
received the injection but had a lower baseline SPADI 
score (–0·36 [–6·87 to 6·16]; appendix pp 13–18). No 
serious adverse events were reported. Three participants 
reported undergoing surgery to repair rotator cuff tear 
(n=1; injection plus progressive exercise), frozen shoulder 
that developed after randomisation (n=1; best practice 
advice), and subacromial decompression and repair of 
rotator cuff tear (n=1; injection plus best practice advice).
The base-case cost-effectiveness analysis showed that 
over the 12-month period, participants in the best 
practice group accrued on average 0·737 QALYs (95% CI 
0·710–0·763) and an NHS cost of £195 per patient 
(appendix p 11). Adding progressive exercise to best 
practice advice gained an additional 0·019 QALYs 
(p=0·22) at an additional NHS and PSS cost of £52 per 
patient (p=0·25; appendix p 11). Adding corticosteroid 
injection to best practice advice gained 0·021 QALYs 
(p=0·18) and increased the total NHS and PSS cost by 
£10 per patient (p=0·75). At a ceiling ratio of £20 000 per 
QALY, best practice advice plus injection was found to 
have a 54·93% probability of being best value for 
money (appendix p 19). Best practice advice plus 
injection cost £476 per QALY gained compared with best 
practice advice alone. This combination of treatments 
was more cost-effective than progressive exercise alone 
and progressive exercise plus injection, being non-
significantly less costly and accruing more QALYs. 
Sensitivity analyses assuming additive effects, taking a 
societal perspective, and varying the cost of training 
physiotherapists con firmed the base-case conclusion 
that best practice advice plus injection is expected to be 
the best value for money in the UK, at a ceiling ratio of 
£20 000 per QALY.23
Discussion
To our knowledge, the GRASP trial is the largest 
randomised controlled trial to date that has investigated 
the effects of exercise interventions and corticosteroid 
injections in adults with a new episode of shoulder pain 
attributable to a rotator cuff disorder. Our findings 
showed no difference in the primary outcome (SPADI 
score) or other prespecified secondary outcomes 
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either progres sive exercise compared with best 
practice advice, or subacromial corticosteroid injection 
compared with no injection, when analysed over 
12 months. We found some evidence that corticosteroid 
injection improves shoulder pain and function at 
8 weeks. The greatest benefit was in the subgroup of 
participants who reported high SPADI scores at baseline 
but because this finding was based on subgroup analysis 
it should be viewed with caution. Irrespective of 
allocated intervention, participants’ shoulder pain and 
function improved over time, although SPADI scores at 
12 months showed that the condition did not resolve 
completely. The most cost-effective intervention in the 
UK was the best practice advice session with a 
physiotherapist plus corticosteroid injection, although 
substantial uncertainty exists around this conclusion. 
Although the benefits of corticosteroid injection were 
limited both in size and to the early phase of recovery 
this combination of inter ventions was best in terms of 
their cost-effectiveness.
A Cochrane review published in 2016 highlighted 
insufficient evidence about the long-term effects of 
treatments offered by physiotherapists for rotator cuff 
disorders.4 In our own systematic review we identified 
seven trials24–30 between 2013 and 2020, comparing the 
effects of supervised versus unsupervised exercise, or no 
intervention, in people with a rotator cuff disorder. All 
the trials were small, apart from two moderate sized 
trials with 271 and 256 participants each,28,30 and only 
two26,30 reported on the effect of exercise on shoulder pain 
and function at 12 months, four reported medium-term 
follow-up data (4–6 months), and the remaining three 
reported outcomes at 6 weeks or less. Most studies 
concluded little or no difference between supervised and 
unsupervised exercise at 6 months and 12 months, with 
the exception of the SUPPORT trial,30 which showed a 
benefit of supervised exercise compared with a simple 
exercise leaflet at 6 months but not at 12 months.
Despite widespread use of corticosteroid injection for 
treating tendinopathy,9 we only identified one small 
trial31 comparing the effects of corticosteroid injection 
versus no injection in people with a rotator cuff 
disorder. This trial found no difference in shoulder 
pain and function when analysed at 3 months or 
6 months. An additional ten trials compared the effects 
of corticosteroid injection versus placebo injection; 
three assessed shoulder pain and function showing 
benefit of injection in the short term (≤8 weeks) but not 
medium term (3–6 months; unpublished). No trials 
provided data beyond 6-month follow-up and none 
reported any serious adverse events as a result of 
injection. Poor response from injection has been 
attributed to inaccurate placement of the injection.30 
However, high quality evidence from the SUPPORT 
trial shows that ultrasound guidance conferred no 
additional benefit over unguided corticosteroid 
injection.30 These findings reinforce the importance of 
the GRASP trial findings in terms of their definitive 
nature, length of follow-up, and short-term benefit of 
corticosteroid injection.
The strength of the GRASP trial, as a definitive, 
multicentre, factorial, randomised controlled trial, is 
that in the absence of any significant interaction we were 
able to assess the effects of our two main intervention 
comparisons. We recruited 708 participants and had a 
lower-than-estimated loss-to-follow-up rate of 13% at 
12 months, so the trial was adequately powered to detect 
a statistically and clinically important difference between 
interventions should one have been present. Participants 
were recruited from 20 NHS trusts in the UK, which in 
terms of location and size make the sample fairly 
representative of NHS patients as a whole. Physio-
therapists were trained to deliver either best practice 
advice or progressive exercise to minimise possible 
contamination between treatment groups. Only two 
physiotherapists swapped treatment groups during the 
trial and delivered both interventions. Despite some 
Figure 2: Marginal adjusted mean SPADI scores from baseline to 12 months
Results are from the repeated measures mixed-effects model. Figure shows progressive exercise (A) and 
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initial concerns from physiotherapists raised during site 
training regarding the adequacy of a single session to 
start the self-guided best practice advice exercise 
programme, very few participants required an additional 
contact session during the trial.
A limitation was that we could not mask participants 
and treating physiotherapists because of the nature of the 
interventions being tested, reflecting a difficulty that is 
common to pragmatic rehabilitation trials. This lack 
of masking reflected in the open-label design has the 
potential to overestimate as opposed to underestimate the 
treatment effect, thus strengthening our findings, which 
showed no difference between treatment interventions 
over 12 months. When practical, members of the trial 
Best practice advice Progressive exercise Between-group 
adjusted difference 
(95% CI)




Adjusted mean (SE) Adjusted mean (SE) Adjusted mean (SD) Adjusted mean (SE)
SPADI pain subscale score
8 weeks 49·9 (1·4); n=300 25·9 (1·3); n=316 2·12 (–1·94 to 6·17) 0·31 49·9 (1·4); n=300 42·9 (1·4); n=315 –7·38 (–11·10 to –3·67) <0·0001
6 months 32·0 (1·4); n=289 20·6 (1·3); n=307 –3·06 (–7·16 to 1·04) 0·14 32·0 (1·4); n=289 32·9 (1·4); n=306 0·89 (–2·88 to 4·66) 0·64
12 months 25·8 (1·4); n=290 39·5 (1·3); n=307 –4·01 (–8·11 to 0·09) 0·055 25·8 (1·4); n=290 27·8 (1·4); n=306 2·05 (–1·72 to 5·81) 0·29
Over 12 months 36·0 (1·3); n=339 34·5 (1·2); n=343 –1·61 (–4·94 to 1·72) 0·34 36·0 (1·3); n=339 34·5 (1·1); n=343 –1·55 (–4·46 to 1·37) 0·30
SPADI function subscale score
8 weeks 29·40 (1·24); n=298 31·77 (1·19); n=316 2·37 (–1·01 to 5·76) 0·17 32·59 (1·18); n=301 28·75 (1·16); n=313 –3·84 (–6·95 to –0·73) 0·015
6 months 20·95 (1·26); n=288 20·65 (1·21); n=307 –0·30 (–3·72 to 3·12) 0·86 20·69 (1·19); n=289 20·89 (1·17); n=306 0·20 (–2·95 to 3·35) 0·90
12 months 18·74 (1·26); n=288 16·12 (1·20); n=307 –2·61 (–6·03 to 0·81) 0·13 16·38 (1·19); n=290 18·34 (1·17); n=305 1·97 (–1·18 to 5·11) 0·22
Over 12 months 23·1 (1·0); n=339 22·9 (1·0); n=343 –0·15 (–2·92 to 2·61) 0·91 23·31 (0·93); n=339 22·72 (0·92); n=343 –0·59 (–3·02 to 1·83) 0·63
EQ-5D-5L
8 weeks 0·71 (0·01); n=274 0·69 (0·01); n=303 –0·02 (–0·05 to 0·00) 0·091 0·69 (0·01); n=278 0·71 (0·01); n=299 0·03 (0·00 to 0·05) 0·045
6 months 0·75 (0·01); n=273 0·74 (0·01); n=291 –0·00 (–0·03 to 0·02) 0·74 0·75 (0·01); n=273 0·74 (0·01); n=291 –0·01 (–0·03 to 0·02) 0·71
12 months 0·77 (0·01); n=281 0·78 (0·01); n=290 0·01 (–0·02 to 0·04) 0·51 0·78 (0·01); n=276 0·76 (0·01); n=295 –0·02 (–0·05 to 0·01) 0·16
Over 12 months 0·74 (0·01); n=330 0·74 (0·01); n=332 –0·01 (–0·03 to 0·02) 0·57 0·74 (0·01); n=319 0·74 (0·01); n=343 0·00 (–0·02 to 0·02) 0·92
Fear-avoidance belief questionnaire (physical activity)
8 weeks 11·62 (0·37); n=269 11·94 (0·35); n=301 0·32 (–0·68 to 1·33) 0·53 12·02 (0·36); n=274 11·59 (0·35); n=296 –0·43 (–1·39 to 0·53) 0·38
6 months 9·93 (0·37); n=266 9·51 (0·36); n=281 –0·42 (–1·44 to 0·60) 0·42 9·70 (0·37); n=262 9·72 (0·35); n=285 0·03 (–0·95 to 1·01) 0·95
12 months 9·29 (0·37); n=266 8·32 (0·36); n=284 –0·97 (–1·99 to 0·05) 0·061 8·55 (0·37); n=265 9·01 (0·35); n=285 0·47 (–0·51 to 1·44) 0·35
Over 12 months 10·3 (0·30); n=324 9·94 (0·28); n=332 –0·35 (–1·16 to 0·46) 0·40 8·22 (0·10); n=316 8·41 (0·10); n=340 0·02 (–0·74 to 0·77) 0·97
Pain self-efficacy questionnaire
8 weeks 10·25 (0·13); n=271 10·19 (0·12); n=300 –0·06 (–0·39 to 0·27) 0·74 10·13 (0·13); n=275 10·30 (0·12); n=296 0·17 (–0·16 to 0·50) 0·31
6 months 10·41 (0·13); n=267 10·42 (0·13); n=282 0·01 (–0·33 to 0·34) 0·96 10·44 (0·13); n=264 10·39 (0·13); n=285 –0·05 (–0·38 to 0·28) 0·77
12 months 10·59 (0·13); n=267 10·70 (0·13); n=284 0·12 (–0·22 to 0·45) 0·49 10·80 (0·13); n=266 10·50 (0·13); n=285 –0·30 (–0·63 to 0·03) 0·078
Over 12 months 10·41 (0·10); n=325 10·43 (0·10); n=332 0·02 (–0·23 to 0·27) 0·86 10·45 (0·10); n=317 10·40 (0·10); n=340 –0·06 (–0·31 to 0·19) 0·66
Insomnia severity index
8 weeks 7·46 (0·32); n=267 8·09 (0·31); n=294 0·63 (–0·25 to 1·50) 0·16 8·57 (0·31); n=270 7·07 (0·30); n=291 –1·50 (–2·32 to –0·68) 0·0003
6 months 6·20 (0·32); n=264 6·20 (0·31); n=281 –0·01 (–0·89 to 0·88) 0·99 6·21 (0·31); n=262 6·18 (0·30); n=283 –0·03 (–0·86 to 0·80) 0·95
12 months 5·92 (0·32); n=267 5·40 (0·31); n=282 –0·52 (–1·40 to 0·36) 0·25 5·48 (0·31); n=265 5·80 (0·30); n=284 0·32 (–0·51 to 1·15) 0·45
Over 12 months 6·53 (0·27); n=323 6·57 (0·26); n=329 0·04 (–0·69 to 0·77) 0·92 6·77 (0·25); n=314 6·35 (0·25); n=338 –0·41 (–1·08 to 0·26) 0·23
Return to desired activities
8 weeks 6·08 (0·14); n=270 6·33 (0·13); n=297 0·25 (–0·12 to 0·62) 0·19 6·49 (0·14); n=273 5·96 (0·13); n=294 –0·53 (–0·89 to –0·17) 0·0042
6 months 5·42 (0·14); n=267 5·10 (0·14); n=284 –0·31 (–0·69 to 0·06) 0·10 5·27 (0·14); n=266 5·24 (0·14); n=285 –0·03 (–0·39 to 0·34) 0·89
12 months 4·81 (0·14); n=268 4·67 (0·14); n=285 –0·14 (–0·51 to 0·24) 0·47 4·63 (0·14); n=268 4·84 (0·14); n=285 0·21 (–0·15 to 0·57) 0·26
Over 12 months 5·44 (0·11); n=325 5·38 (0·11); n=332 –0·06 (–0·36 to 0·23) 0·66 5·47 (0·11); n=317 5·35 (0·11); n=340 –0·12 (–0·40 to 0·16) 0·41
Global impression of treatment
8 weeks 7·65 (0·13); n=269 7·75 (0·13); n=298 0·11 (–0·25 to 0·47) 0·56 7·34 (0·13); n=273 8·03 (0·13); n=294 0·69 (0·35 to 1·03) <0·0001
6 months 8·16 (0·13); n=267 8·69 (0·13); n=285 0·53 (0·17 to 0·90) 0·0038 8·42 (0·13); n=267 8·45 (0·13); n=285 0·04 (–0·31 to 0·39) 0·83
12 months 8·57 (0·13); n=270 9·08 (0·13); n=286 0·51 (0·14 to 0·87) 0·0060 8·91 (0·13); n=269 8·76 (0·13); n=287 –0·14 (–0·49 to 0·20) 0·42
Over 12 months 8·12 (0·10); n=326 8·50 (0·10); n=332 0·38 (0·10 to 0·66) 0·0074 8·22 (0·10); n=317 8·41 (0·10); n=347 0·20 (–0·06 to 0·46) 0·14
SPADI=shoulder pain and disability index. *Outcome analysis adjusted for age, sex, and baseline outcome value, with random effects within participant, physiotherapist, and centre.
Table 4: Adjusted mean differences for secondary outcomes for best practice advice vs progressive exercise and injection vs no injection
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team were masked until after data analysis was complete, 
with the exception of the data entry personnel who 
entered data from anonymised questionnaires, which 
included some details on treatments received. Data entry 
was checked as part of quality assurance processes and 
any bias associated with this process was considered 
minimal. Additionally, a masked analysis of data was 
undertaken before the final data lock.
Early and effective management of rotator cuff 
disorders is important given evidence from the CSAW 
(Can Shoulder Arthroscopy Work) trial32 and updated 
Cochrane review33 showing no benefit from subacromial 
decom pression surgery. Subacromial corticosteroid 
injection, although providing modest short-term benefit, 
was associated with participants being more likely to 
report doing their exercises as advised (ie, 5 days per 
week) in both the progressive exercise and best practice 
advice intervention groups. Physiotherapists delivering 
the best practice advice focused on strategies to promote 
self-management and independent progression of 
exercise, adherence to exercise, and addressing barriers 
to exercise. The exercises prescribed were those within 
the range that physiotherapists deliver in usual practice. 
As a result, we believe the implementation of the best 
practice advice intervention into the NHS would be 
straightforward and involve somewhat small training 
costs. For some patients, a single session might not be 
appropriate—eg, those with low levels of literacy or 
inability to engage with self-management care, in which 
case additional physiotherapy sessions might be 
required.
Our population was predominantly White British, 
with the proportion of such participants higher than 
that of the population in England as a whole.34 The 
prevalence of rotator cuff disorder in ethnic minority 
groups is not well known or understood and so inferring 
what influence this over-representation might have on 
the generalisability of our results is difficult. Some 
participants reported ongoing pain and impaired 
shoulder function at 12 months; thus future research is 
needed to better understand the natural history of 
rotator cuff disorders, including whether symptoms 
resolve over an extended time period. Very few 
participants reported undergoing surgery and extended 
follow-up would also address concerns regarding later 
surgery and possible long-term harm after corticosteroid 
injection and surgery’s potential effects on tendon 
structure.
In conclusion, the GRASP trial showed that 
progressive exercise was not superior to a best practice 
advice session with a physiotherapist. Subacromial 
corticosteroid injec tion improved shoulder pain and 
function and provided modest short-term benefit. Best 
practice advice in combination with corticosteroid 
injection is expected to be the most cost-effective 
treatment combination for use of NHS resources, 
although this conclusion is uncertain.
Contributors
SH and SEL were co-chief investigators and co-lead applicants. 
All authors contributed to the trial design, interpretation of data, and 
critical revision of the final version of the report. DJK led development 
and implementation of the exercise interventions. PH trained 
physiotherapists and monitored intervention fidelity. IRM conducted the 
statistical analysis and SJD provided statistical and trial design expertise. 
MD conducted the health economic analysis. HD and AG provided 
health economics expertise. LC provided trial management expertise. 
AC, WH, ZH, AJ, CL, KLB, and DJK provided clinical expertise. 
SH, SEL, DJK, IRM, and MD led on writing the manuscript. All authors 
read, commented on, and approved the final version. SH and SEL 
verified the underlying data. All authors had full access to all the data in 
the study and had final responsibility for the decision to submit for 
publication.
GRASP Trial Group
Principal investigators: Marcus Bateman (University Hospitals of Derby 
and Burton NHS Foundation Trust), Alison Hallett and Helen Thompson 
(East Lancashire Hospitals NHS Trust), Elaine Willmore 
(Gloucestershire Hospitals NHS Foundation Trust), Lucy McCann and 
Jonathan Price (Birmingham Community Healthcare NHS Trust), 
Neil Smith (Sandwell and West Birmingham Hospitals NHS Trust), 
Harry Kardamilas (Buckinghamshire Musculoskeletal Integrated Care 
Service), Matt Hurst (East Cheshire Hospitals NHS Trust), Tim Andrews 
and Lori Wells (Bedford Hospitals NHS Trust), Chole De Matas (Wirral 
University Teaching Hospital NHS Foundation Trust), Arun Jaykumar 
(Medway Community Healthcare), Sean Grove (Bristol Community 
Health), Corinne Birch (Somerset Partnership NHS Foundation Trust), 
Julie Bury (Doncaster & Bassetlaw Teaching Hosptials NHS Foundation 
Trust), James Blacknall (Sherwood Forest Hospitals NHS Foundation 
Trust), Sally Jessep and Llewelyn Boucher (Kent Community Health 
NHS Foundation Trust), Robert Sandbach (Northern Devon Healthcare 
NHS Trust), Stacey Lalande (Airedale NHS Foundation Trust), 
Gill Dickson (North West Boroughs Healthcare NHS Foundation Trust), 
Treena Larkin (Staffordshire and Stoke on Trent Partnership NHS 
Foundation Trust), and Carole Cummings (Warrington & Halton 
Hospitals NHS Foundation Trust). Trial steering committee: Neal Millar 
(University of Glasgow), Chris Metcalfe (University of Bristol), 
Rebecca Kearney (University of Warwick), Melinda Cairns (University of 
Hertfordshire), Sue Jowett (University of Birmingham), Richard Goodier 
(patient representative), Jean Millar (patient representative). 
Data monitoring and ethics committee: Mike Clarke (Queen’s University 
Belfast), Brennan Kahan (Queen Mary University of London), 
Alison Rushton (University of Birmingham), and Jessica Watson 
(University of Bristol). GRASP trial management team: Sally Hopewell 
(co-chief investigator; University of Oxford), Lucy Cureton (trial 
manager; University of Oxford), Adam Pritchard (trial administrator; 
University of Oxford), Peter Heine (research physiotherapist; University 
of Oxford), David Keene (lead physiotherapist; University of Oxford), 
Ioana Marian (statistician; University of Oxford), Melina Dritsaki (health 
economist; University of Oxford), and Sallie Lamb (co-chief investigator; 
University of Oxford).
Declaration of interests
SH is a member of the UK National Institute for Health Research (NIHR) 
Health Technology Assessment (HTA) Clinical Evaluation and Trials 
Committee (Nov 1, 2018, to Nov 30, 2022). DJK holds an NIHR 
postdoctoral fellowship. IRM holds an NIHR pre-doctoral fellowship. 
SJD reports grants from the NIHR HTA programme during the conduct 
of the study. HD is partly funded by an NIHR senior research fellowship 
through the Biomedical Research Centre, Oxford, UK. AC is a member of 
the UK Research and Innovation/Medical Research Council 
Developmental Pathway Funding Scheme panel. He was chief 
investigator of the NIHR HTA UK Rotator Cuff Surgery (UKCUFF) trial 
and the CSAW trial. He is a consultant to the Novartis musculoskeletal 
board. He is chief investigator of an NIHR i4i trial of a novel electrospun 
patch and of a Wellcome Trust-funded trial of a novel electrospun suture 
in rotator cuff repair surgery. He was director of the NIHR 
Musculoskeletal British Research Unit from 2008 to 2017 and is 
musculoskeletal theme lead for the NIHR Oxford comprehensive British 
Research Centre. ZH reports grants from the NIHR HTA programme 
Articles
12 www.thelancet.com   Published online July 12, 2021   https://doi.org/10.1016/S0140-6736(21)00846-1
during the conduct of the study and is paid personal fees by various 
health-care trusts and individuals to train health-care professionals in 
cognitive behavioural approaches, outside the submitted work. AJ is a 
council member of the British Shoulder and Elbow Society. She is 
co-applicant for the NIHR HTA (Partial Rotator Cuff Tear Repair 
(PROCURE) trial. CL is chair of the Chartered Society of Physiotherapy 
scientific panel. He is chief investigator of the NIHR post-doctoral 
fellowship-funded Surgery versus PhysiothErapist-leD exercise (SPeEDy) 
study. He was previously lead researcher for the NIHR Research for 
Patient Benefit funded Rehabilitation Following Rotator Cuff Repair 
(RaCeR) study and chief investigator for the NIHR doctoral fellowship-
funded SELF (a self-managed single exercise programme versus usual 
physiotherapy treatment for rotator cuff tendinopathy) study. SEL reports 
grants from the NIHR HTA programme during the conduct of the study 
and was a member of the following boards: HTA Additional Capacity 
Funding Board 2012–15; HTA Clinical Trials Board 2010–15; HTA End of 
Life Care and Add on Studies 2015–15; HTA Funding Boards Policy Group 
(formerly CSG) 2010–15; HTA Maternal, Neonatal and Child Health 
Methods Group 2013–15; HTA post-board funding teleconference 
(Prioritisation Group members to attend) 2010–15; HTA Primary Care 
Themed Call board 2013–14; HTA Prioritisation Group 2010–15; and 
NIHR Clinical Trials Unit Standing Advisory Committee 2012–16. 
All other authors declare no completing interests.
Data sharing
All data requests should be submitted to the corresponding author (SH) 
for consideration as agreed in our publication plan. Access to anonymised 
data may be granted following review with the trial management group 
and agreement of the co-chief investigators (SH and SEL).
Acknowledgments
This research was funded by the NIHR HTA Programme (grant 
15/26/06). Foremost, we thank the patients participating in this trial, 
without whom this trial would have not been possible. We would like to 
thank those who made a substantial contribution to the study but are not 
named as authors: Debbie Brown (research physiotherapist) for her 
assistance with development of the GRASP exercise interventions; 
Hessam Soutakbar (research physiotherapist) for his assistance with 
GRASP exercise intervention site training and monitoring; 
Jacqueline Thompson (research physiotherapist) for her assistance with 
GRASP participant telephone follow-up; Emma Searle (MSc student, 
Université Paris Descartes, Paris, France) for her help with updating the 
literature search. The GRASP trial was done as part of the portfolio of 
trials in the registered UK Registered Clinical Trials Units Oxford Clinical 
Trials Research Unit at the University of Oxford, Oxford, UK. The trial 
has followed their standard operating procedures ensuring compliance 
with the principles of Good Clinical Practice and the Declaration of 
Helsinki and any applicable regulatory requirements.
References
1 Mitchell C, Adebajo A, Hay E, Carr A. Shoulder pain: diagnosis and 
management in primary care. BMJ 2005; 331: 1124–28.
2 Linsell L, Dawson J, Zondervan K, et al. Prevalence and incidence of 
adults consulting for shoulder conditions in UK primary care; 
patterns of diagnosis and referral. Rheumatology 2006; 45: 215–21.
3 British Elbow and Shoulder Society, British Orthopaedic 
Association, Royal College of Surgeons. Commissioning guide: 
subacromial shoulder pain. 2014. https://www.rcseng.ac.uk/library-
and-publications/rcs-publications/docs/subacromial-shoulder-pain/ 
(accessed June 21, 2021).
4 Page MJ, Green S, McBain B, et al. Manual therapy and exercise for 
rotator cuff disease. Cochrane Database Syst Rev 2016; 6: CD012224.
5 Hanratty CE, McVeigh JG, Kerr DP, et al. The effectiveness of 
physiotherapy exercises in subacromial impingement syndrome: 
a systematic review and meta-analysis. Semin Arthritis Rheum 2012; 
42: 297–316.
6 Littlewood C, Ashton J, Chance-Larsen K, May S, Sturrock B. 
Exercise for rotator cuff tendinopathy: a systematic review. 
Physiotherapy 2012; 98: 101–09.
7 Littlewood C, Malliaras P, Chance-Larsen K. Therapeutic exercise for 
rotator cuff tendinopathy: a systematic review of contextual factors 
and prescription parameters. Int J Rehabil Res 2015; 38: 95–106.
8 Buchbinder R, Green S, Youd JM. Corticosteroid injections for 
shoulder pain. Cochrane Database Syst Rev 2003; 2003: CD004016.
9 Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of 
corticosteroid injections and other injections for management of 
tendinopathy: a systematic review of randomised controlled trials. 
Lancet 2010; 376: 1751–67.
10 Hopewell S, Keene DJ, Maia Schlüssel M, et al. Clinical and 
cost-effectiveness of progressive exercise compared with best 
practice advice, with or without corticosteroid injection, for the 
treatment of rotator cuff disorders: protocol for a 2 × 2 factorial 
randomised controlled trial (the GRASP trial). BMJ Open 2017; 
7: e018004.
11 Marian IR, Hopewell S, Keene DJ, Cureton L, Lamb SE, Dutton SJ. 
Progressive exercise compared with best practice advice, with or 
without corticosteroid injection, for the treatment of rotator cuff 
disorders: statistical analysis plan for the Getting it Right: 
Addressing Shoulder Pain (GRASP) 2 × 2 factorial multicentre 
randomised controlled trial. Trials 2020; 21: 767.
12 Dritsaki M, Dakin H, Hopewell S, Lamb SE. Clinical and cost 
effectiveness of progressive exercise compared to best practice 
advice, with or without corticosteroid injection, for the treatment 
of rotator cuff disorders: a 2×2 factorial randomised controlled 
trial—health economics analysis plan. https://ora.ox.ac.uk/
objects/uuid:e33a9c3c-2b7f-4c5a-969f-d31729652c9c (accessed 
Oct 21, 2020).
13 Keene DJ, Soutakbar H, Hopewell S, et al. Development and 
implementation of the physiotherapy-led exercise interventions for 
the treatment of rotator cuff disorders for the ‘Getting it Right: 
Addressing Shoulder Pain’ (GRASP) trial. Physiotherapy 2020; 
107: 252–66.
14 Williams JW Jr, Holleman DR Jr, Simel DL. Measuring shoulder 
function with the Shoulder Pain and Disability Index. J Rheumatol 
1995; 22: 727–32.
15 Brooks R. EuroQol: the current state of play. Health Policy 1996; 
37: 53–72.
16 Mintken PE, Cleland JA, Whitman JM, George SZ. Psychometric 
properties of the fear-avoidance beliefs questionnaire and Tampa 
scale of kinesiophobia in patients with shoulder pain. 
Arch Phys Med Rehabil 2010; 91: 1128–36.
17 Nicholas MK, McGuire BE, Asghari A. A 2-item short form of the 
pain self-efficacy questionnaire: development and psychometric 
evaluation of PSEQ-2. J Pain 2015; 16: 153–63.
18 Bastien CH, Vallières A, Morin CM. Validation of the insomnia 
severity index as an outcome measure for insomnia research. 
Sleep Med 2001; 2: 297–307.
19 Kamper SJ, Maher CG, Mackay G. Global rating of change scales: 
a review of strengths and weaknesses and considerations for 
design. J Manual Manip Ther 2009; 17: 163–70.
20 Roach KE, Budiman-Mak E, Songsiridej N, Lertratanakul Y. 
Development of a shoulder pain and disability index. 
Arthritis Care Res 1991; 4: 143–49.
21 Breckenridge JD, McAuley JH. Shoulder Pain and Disability Index 
(SPADI). J Physiother 2011; 57: 197.
22 National Institute for Health Care Excellence. Guide to the methods 
of technology appraisal. 2013. https://www.nice.org.uk/article/
pmg9/chapter/Foreword (accessed March 2, 2021).
23 Hopewell S, Keene DJ, Heine P, et al. Progressive exercise 
compared with best practice advice, with or without corticosteroid 
injection, for rotator cuff disorders: the GRASP factorial RCT. 
Health Technol Assess (in press).
24 Krischak G, Gebhard F, Reichel H, et al. A prospective randomized 
controlled trial comparing occupational therapy with home-based 
exercises in conservative treatment of rotator cuff tears. 
J Shoulder Elbow Surg 2013; 22: 1173–79.
25 Granviken F, Vasseljen O. Home exercises and supervised exercises 
are similarly effective for people with subacromial impingement: 
a randomised trial. J Physiother 2015; 61: 135–41.
26 Littlewood C, Bateman M, Brown K, et al. A self-managed single 
exercise programme versus usual physiotherapy treatment for 
rotator cuff tendinopathy: a randomised controlled trial (the SELF 
study). Clin Rehabil 2016; 30: 686–96.
27 Asensio-García MDR, Bernabeú-Casas RC, Palazón-Bru A, 
Tomás-Rodríguez MI, Nouni-García R. Effectiveness of a group 
physiotherapy intervention in nontraumatic, inoperable painful 
shoulder: a randomized clinical trial. Am J Phys Med Rehabil 2018; 
97: 110–15.
Articles
www.thelancet.com   Published online July 12, 2021   https://doi.org/10.1016/S0140-6736(21)00846-1 13
28 Contreras J, Liendo R, Díaz C, et al. Effectiveness of a self-
administered rehabilitation program for shoulder pain syndrome in 
primary health care. Rev Med Chil 2018; 146: 959–67 (in Spanish).
29 Türkmen E, Analay Akbaba Y, Altun S. Effectiveness of video-based 
rehabilitation program on pain, functionality, and quality of life in 
the treatment of rotator cuff tears: a randomized controlled trial. 
J Hand Ther 2020; 33: 288–95.
30 Roddy E, Ogollah RO, Oppong R, et al. Optimising outcomes of 
exercise and corticosteroid injection in patients with subacromial 
pain (impingement) syndrome: a factorial randomised trial. 
Br J Sport Med 2021; 55: 262–71.
31 Gialanella B, Prometti P. Effects of corticosteroids injection in 
rotator cuff tears. Pain Med 2011; 12: 1559–65.
32 Beard DJ, Rees JL, Cook JA, et al. Arthroscopic subacromial 
decompression for subacromial shoulder pain (CSAW): 
a multicentre, pragmatic, parallel group, placebo-controlled, 
three-group, randomised surgical trial. Lancet 2018; 391: 329–38.
33 Karjalainen TV, Jain NB, Page CM, et al. Subacromial decompression 
surgery for rotator cuff disease. Cochrane Database Syst Rev 2019; 
1: CD005619.
34 Office for National Statistics. Ethnicity. https://www.ons.gov.uk/
peoplepopulationandcommunity/culturalidentity/ethnicity 
(accessed June 21, 2021).
